Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Proposed Acquisition of European Medical Testing Subsidiary (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News FibroGen Inc FGEN

Healthcare Biotechnology
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor ... see more

Recent & Breaking News (NDAQ:FGEN)

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Newsfile April 27, 2021

FGEN LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving FibroGen, Inc.

Newsfile April 27, 2021

SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS DOX, FGEN, GOEV, GOEVW INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

GlobeNewswire April 26, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN

PR Newswire April 26, 2021

ROSEN, A LEADING AND LONGSTANDING LAW FIRM, Encourages FibroGen, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline - FGEN

PR Newswire April 26, 2021

FGEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 11, 2021 in the Class Action Filed on Behalf of FibroGen, Inc. Limited Shareholders

Newsfile April 26, 2021

FIBROGEN INVESTORS: June 11, 2021 Filing Deadline in Class Action - Contact Lieff Cabraser

Business Wire April 26, 2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN

Newsfile April 26, 2021

FGEN SHAREHOLDER FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Fibrogen Inc.

GlobeNewswire April 26, 2021

INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

ACCESSWIRE IA April 26, 2021

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds FibroGen (FGEN) Investors to Securities Fraud Lawsuit and Application Deadline, Encourages Investors with Losses to Contact Its Attorneys Now

GlobeNewswire April 26, 2021

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Newsfile April 26, 2021

CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds FibroGen, Inc. Shareholders of Securities Fraud Class Action Lawsuit

Newsfile April 26, 2021

Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc.

GlobeNewswire April 25, 2021

FibroGen, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm

GlobeNewswire April 25, 2021

FibroGen Class Action Reminder

Newsfile April 25, 2021

ROSEN, NATIONAL TRIAL COUNSEL, Encourages FibroGen, Inc. Investors with Losses to Secure Counsel Before Important Deadline - FGEN

GlobeNewswire April 24, 2021

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

ACCESSWIRE IA April 24, 2021

Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc. (FGEN)

PR Newswire April 24, 2021

SHAREHOLDER ALERT: CLAIMSFILER REMINDS CAN, CS, DOX, FGEN INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

GlobeNewswire April 23, 2021